The European Medicines Agency (EMA) proposed a centralized support platform to standardize clinical trial contracting across the EU, aiming to reduce delays that sponsors face when negotiating site and CRO agreements. In its clinical trial highlights newsletter, the agency said contractual negotiations remain a “central challenge” and that current template availability varies widely by member state. EMA’s analysis highlighted gaps for multi-country, multi-site studies, noting that existing national and regional templates often don’t cover complex cross-border setups. Stakeholders including EFPIA and EUCROF backed the need for faster, harmonized contracting processes. For sponsors, the EMA move signals a near-term push toward more operationally consistent start-up timelines—an issue that increasingly affects which programs reach patients first in Europe.